Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.2752W HIGH $1.20
Volume
317.82 K
Value Traded
313.15 K
Short % Float
5.33%
Days to Cover
6.4
-2.94%Week
-1.68%1 Month
+141.75%3 Month
+97.92%6 Month
-96.38%5 Year
-97.56%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
47.64 M
EPS (TTM)
-0.71
P/E Ratio
-
Ent. Value
5.77 M
Total Shares
48.62 M
Float Shares
39.93 M
Insiders
17.84%
Institutions
22.67%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
HOWL Catalyst Timeline
Dated clinical, regulatory and corporate events for Werewolf Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Werewolf Therapeutics, Inc.
262Total events
14Upcoming
31Tier-1 (high impact)
2021 to 2045Coverage
Upcoming catalysts 2
Event history 50
●Poster PresentationWTX-330Presentation
Poster presented at SITC 2026 for WTX-330 Phase 1b/2 data
relapsed/refractory, locally advanced or metastatic solid tumorssource ↗
▲Full ResultsWTX-124Clinical Data
Phase 1/1b WTX-124 data (database lock June 4, 2026) presented at SITC 2026
relapsed/refractory, immunotherapy-sensitive locally advanced or metastatic solid tumorssource ↗
▲Full ResultsWTX-330Clinical Data
Phase 1b/2 WTX-330 data (database lock May 14, 2026) presented at SITC 2026
relapsed/refractory, locally advanced or metastatic solid tumorssource ↗
●Poster PresentationWTX-124Presentation
Poster presented at SITC 2026 for WTX-124 Phase 1/1b data
relapsed/refractory, immunotherapy-sensitive locally advanced or metastatic solid tumorssource ↗
●Late-BreakerWTX-124Presentation
Late-breaking abstract for WTX-124 presented at SITC 2026
relapsed/refractory, immunotherapy-sensitive locally advanced or metastatic solid tumorssource ↗
◆AcquisitionCorporate
Werewolf Therapeutics and Ambros Therapeutics announce definitive merger agreement
▲Partnership / LicenseJZP898Corporate
Entered into asset purchase agreement with Jazz Pharmaceuticals for JZP898 program
▲Debt Royalty FinancingCorporate
Repaid all amounts owed under loan and security agreement with K2 HealthVentures
▲Safety Data UpdateWTX-124Clinical Data
WTX-124 Phase 1/1b data (database lock June 4, 2026) with durable responses and outpatient safety
relapsed/refractory, immunotherapy-sensitive locally advanced or metastatic solid tumorssource ↗
▲Safety Data UpdateWTX-330Clinical Data
WTX-330 Phase 1b/2 data (database lock May 14, 2026) with improved tolerability and partial response
relapsed/refractory, locally advanced or metastatic solid tumorssource ↗
▲Partnership / LicenseJZP898Corporate
Asset purchase agreement with Jazz Pharmaceuticals for JZP898
IFN programsource ↗
▲Debt Royalty FinancingCorporate
Repayment of loan and security agreement with K2 HealthVentures
▲Partnership / LicenseJZP898Corporate
Entered into asset purchase agreement with Jazz Pharmaceuticals for JZP898 program
▲Debt Royalty FinancingCorporate
Repaid all amounts owed under loan and security agreement with K2 HealthVentures
◆Pipeline PrioritizationCorporate
Initiated process to explore strategic alternatives including sale, merger, or licensing
◆Pipeline PrioritizationCorporate
Company announces exploration of strategic alternatives including sale, merger, or licensing
◆Topline ReadoutWTX-124Clinical Data
Final Phase 1/1b data anticipated in 1H26
advanced/metastatic cancerssource ↗
◆Topline ReadoutWTX-330Clinical Data
Phase 1b/2 update anticipated in 1H26
advanced/metastatic cancerssource ↗
●Primary CompletionWTX-330Trial
Completion of Part A of Phase 1b/2 clinical trial
solid tumorssource ↗
▲End Of Phase 1 MeetingWTX-124FDA Meeting
End of Phase 1 meeting with FDA; 18 mg accepted as recommended dose
post-ICI advanced or metastatic relapsed/refractory melanomasource ↗
▲Topline ReadoutWTX-124Clinical Data
Initial Phase 1b expansion arm data: 30% ORR in defined subset
post-ICI advanced or metastatic cutaneous melanomasource ↗
▲Topline ReadoutWTX-330Clinical Data
Initial Phase 1b/2 data: antitumor activity and favorable tolerability
solid tumorssource ↗
◆Poster PresentationPresentation
Development of conditional T cell engagers (INDUCER molecules) with a highly effective masking approach to reduce dose-limiting cytokine release and off-target peripheral toxicity
cancersource ↗
◆Poster PresentationWTX-124Presentation
Pharmacokinetic insight into the IL-2 INDUKINE prodrug WTX-124: real-time assessment of tumor-specific activation and immune modulation
cancersource ↗
●Poster PresentationPresentation
Preclinical data on PREDATOR platform, INDUCER T cell engager platform, and sequential dosing of INDUKINE molecules presented at SITC 2025
cancersource ↗
◆Poster PresentationWTX-124Presentation
Sequential administration of WTX-124 and mWTX-330, IL-2 and IL-12 INDUKINE molecules, enhanced antitumor activity in mice bearing poorly immunogenic EMT6 tumors without systemic toxicity
cancersource ↗
▲Fast Track DesignationWTX-124Designation
FDA grants Fast Track Designation for WTX-124 in cutaneous melanoma
locally advanced or metastatic cutaneous melanoma after standard of care immunotherapysource ↗
◆Topline ReadoutWTX-124Clinical Data
Preliminary data from WTX-124 Phase 1/1b trial expected in Q4 2025
advanced solid tumors including cutaneous melanomasource ↗
◆FDA Feedback ReceivedWTX-124FDA Meeting
Engagement with FDA regarding potential registration strategy for WTX-124 expected in Q4 2025
locally advanced or metastatic cutaneous melanomasource ↗
▲Fast Track DesignationWTX-124Designation
WTX-124 received Fast Track Designation
solid tumorssource ↗
◆End Of Phase 1 MeetingWTX-124FDA Meeting
End of Phase 1 meeting with FDA for WTX-124 expected later in Q4 2025
solid tumorssource ↗
◆Oral PresentationPresentation
Werewolf Therapeutics to participate in fireside chat at H.C. Wainwright 27th Annual Global Investment Conference
◆Oral PresentationWTX-124Presentation
Presentation at KidneyCAN 7th Annual Kidney Cancer Research Summit on WTX-124 early clinical findings
renal cell carcinoma (RCC) and other solid tumorssource ↗
◆Topline ReadoutWTX-124Clinical Data
Interim data from WTX-124 monotherapy and combination expansion arms
multiple solid tumor typessource ↗
◆FDA Feedback ReceivedWTX-124FDA Meeting
FDA interactions to discuss potential registrational pathways for WTX-124
multiple solid tumor typessource ↗
◆Oral PresentationPresentation
Werewolf CMO to participate in panel at BIO International Convention
◆Oral PresentationPresentation
Werewolf Therapeutics to participate in Jefferies Global Healthcare Conference fireside chat
◆Oral PresentationPresentation
Sameer Chopra speaks at Cytokine-Based Drug Development Summit on tumor-activated INDUKINE molecules
cancersource ↗
◆Oral PresentationPresentation
Bank of America Securities 2025 Health Care Conference Fireside Chat
▲First Patient DosedWTX-330Trial
First patient dosed in Phase 1b/2 clinical trial of WTX-330
advanced or metastatic solid tumorssource ↗
Past FDA Catalysts and PDUFA Decisions
How HOWL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-11-07 | WTX-330 | Phase 1b/2 data presentation | Phase 1b/2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 63%
Micro Cap(rank 433 of 687)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| WTX-330 BiologicsCompletedNCT05678998 | Advanced or Metastatic Solid Tumors | Phase 1/2 | COMPLETED | 49 | Feb 5, 2025 | ||||||
| WTX-124 BiologicsCompletedNCT05479812 | Metastatic Solid Tumor | Phase 1 | COMPLETED | 156 | Apr 22, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every HOWL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| WTX-124 Fast Track | solid tumors | Phase 1/1b | 2026-11-09 | three objective responses in dose escalation, including one durable confirmed complete response (CR) in a patient with primary immune checkpoint inhibitor (ICI)-resistant cutaneous squamous cell carcinoma (CSCC) that has remained ongoing without any additional anticancer therapy for approximately three years, and two partial responses in patients with cutaneous melanoma and gastroesophageal junction (GEJ) adenocarcinoma per immune RECIST.Read More | Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| EVNIN LUKEDirector | Sell | -107,429 | $0.31 | 07/07/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in HOWL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 0 % (-100 %) | 859.35 K | 2.39 M | -64.26% ( -4.29 M) |
Ownership Trends
HOWL Short Interest
Shares sold short, counted twice a month.
5.33%
Short % of Float
of tradable shares sold short
2.1M
Shares Sold Short
-9.7% vs prior count
6.4 High
Days to Cover
trading days of normal volume to buy every short share back
333.0K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How HOWL ranks across every disease it competes in
Competitive Position is a premium feature
See how HOWL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialHOWL News
HOWLWerewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting
Werewolf Therapeutics presented new clinical data for WTX-124 and WTX-330 at the SITC 2026 Annual Meeting. WTX-124 was administered safely with durable responses in patients with solid tumors. The FDA has recommended a Phase 2 dose of 18 mg IV Q2W for WTX-124. WTX-330 also showed promising results in patients with advanced solid tumors.
Read more →HOWL▼ -10.4%on this news
Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting
Werewolf Therapeutics has been chosen for an oral presentation and two poster presentations at the Society for Immunotherapy of Cancer's 2026 Annual Meeting. The oral presentation will focus on a Phase 1/1b study of the IL-2 prodrug WTX-124. The event will take place from November 4-8, 2026, in Phoenix, Arizona.
Read more →HOWL▲ +102.6%on this news· ran to +129% by day 3
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement
Werewolf Therapeutics and Ambros Therapeutics have announced a merger agreement to form a new biotechnology company focused on developing neridronate for treating Complex Regional Pain Syndrome Type 1 (CRPS-1). The merger includes a $150 million private placement to fund operations through pivotal trial results and a planned NDA submission. Neridronate has received multiple FDA designations and aims to become the first approved treatment for CRPS-1.
Read more →HOWL▼ -29.4%on this news
Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
Werewolf Therapeutics reported its financial results for Q2 2026, highlighting a net income of $3.7 million, a significant improvement from a net loss of $18 million in Q2 2025. The company received a $21 million payment from Jazz Pharmaceuticals and reported collaboration revenue of $21 million. However, cash reserves have decreased, raising concerns about future funding.
Read more →HOWLWerewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates
Werewolf Therapeutics has released its first-quarter financial results for 2026, demonstrating a reduced net loss of $13.5 million compared to $18.1 million in the prior year. The company is actively exploring strategic options aimed at maximizing shareholder value, including a successful asset purchase agreement with Jazz Pharmaceuticals for the JZP898 program. However, its cash position has declined to $46.5 million from $57.1 million in the last quarter. Ongoing uncertainties surrounding the development of its product candidates were also noted.
Read more →HOWL▼ -9.5%on this news
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Werewolf Therapeutics reported its fourth quarter and full year 2025 financial results, highlighting a strategic evaluation process to maximize stockholder value. The company has engaged Piper Sandler as a financial advisor for potential transactions. Financially, the company showed a decrease in both research and development expenses and net loss compared to 2024.
Read more →HOWLWerewolf Therapeutics Announces Plan to Explore Strategic Alternatives
Werewolf Therapeutics announced plans to explore various strategic alternatives aimed at maximizing stockholder value. The company has engaged Piper Sandler & Co. as its financial advisor for this process. Potential options include a sale of the company, mergers, or collaborations, although no specific timeline or guarantees for success have been provided.
Read more →HOWL▼ -39.6%on this news
Werewolf Therapeutics Announces Pipeline and Business Updates
Werewolf Therapeutics has announced significant advancements in its clinical pipeline, particularly for its candidates WTX-124 and WTX-330. Initial data from the WTX-124 Phase 1b trial indicates a 30% overall response rate as a monotherapy in a specific subset of melanoma patients. Additionally, Phase 1b/2 data for WTX-330 suggests promising tolerability and antitumor activity. The company is focused on securing strategic partnerships for further development and anticipates completing trials for both candidates by mid-2026.
Read more →HOWL▼ -39.6%on this news
Corporate Presentation December 2025 1 | 2025 WEREWOLF THERAPEUTICS 2025 WEREWOLF THERAPEUTICS Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements that involve subst
Werewolf Therapeutics presented forward-looking statements regarding its pipeline and future operations, highlighting key product candidates including WTX-124 and WTX-330, which are in clinical development. The presentation emphasized the company's innovative PREDATOR platform, showcasing its potential to address limitations in existing cancer immunotherapies. Strategic partnerships are being sought to bolster drug development, with notable preliminary clinical trial data suggesting promising safety and efficacy outcomes. However, the company acknowledges the inherent uncertainties of clinical trials and the need for regulatory approvals.
Read more →HOWLWerewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
Werewolf Therapeutics presented preclinical data at the SITC meeting showing its INDUCER platform mitigates toxicity in T cell engagers. Sequential dosing of IL-12 and IL-2 molecules demonstrated superior tumor killing compared to single agents. Real-time data confirmed WTX-124 activates selectively in tumors while sparing healthy tissue. These findings support the company’s strategy to improve safety and efficacy for its cancer candidates.
Read more →HOWL▼ -7.6%on this newsshared move
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Werewolf Therapeutics reported a net loss of $16.4 million for the third quarter of 2025. Cash and cash equivalents stood at $65.7 million as of September 30, 2025. The company plans to provide updates on its WTX-124 and WTX-330 clinical trials later this year. These updates will follow an End of Phase 1 meeting with the FDA.
Read more →HOWLWerewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
Werewolf Therapeutics has received Fast Track Designation from the FDA for WTX-124, an investigational therapy aimed at treating advanced cutaneous melanoma. This designation is intended to expedite the development of drugs addressing serious unmet medical needs. The company is currently evaluating WTX-124 in a Phase 1/1b clinical trial, with preliminary data expected soon.
Read more →HOWL▲ +6.8%on this newsshared move
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
Werewolf Therapeutics, Inc. announced the presentation of three posters at the Society for Immunotherapy of Cancer's 40th Annual Meeting, scheduled for November 5-9, 2025. The posters will showcase research on their conditionally activated therapeutics aimed at enhancing antitumor activity while minimizing toxicity. This highlights the company's commitment to advancing cancer treatment through innovative approaches.
Read more →HOWLWerewolf Therapeutics Receives FDA Fast Track Designation for WTX-124 for the Treatment of Advanced or Metastatic Solid Tumors
Werewolf Therapeutics has announced that its investigational drug WTX-124 has received Fast Track Designation from the FDA. This designation is aimed at facilitating the development of therapies for serious conditions, specifically targeting advanced or metastatic solid tumors. The Fast Track status may accelerate the drug's review process, enhancing its availability to patients.
Read more →HOWLWerewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference
Werewolf Therapeutics will participate in the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. CEO Daniel J. Hicklin and CMO Randi Isaacs will engage in a fireside chat to discuss the company's innovative therapies. The event will be available via live webcast and archived for 90 days.
Read more →HOWLWerewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Werewolf Therapeutics reported its financial results for Q2 2025, highlighting the positive progress of the WTX-124 Phase 1 1b clinical trial, which is set for interim data readout in Q4 2025. The company plans to engage the FDA to discuss potential registrational pathways for WTX-124 in advanced cutaneous melanoma. Additionally, Werewolf introduced WTX-1011, a new T-cell engager candidate for treating prostate cancer. However, the company's financial outlook shows a net loss of $18 million and a reduction in cash reserves over the last quarter.
Read more →HOWLWerewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
Werewolf Therapeutics will present at the KidneyCAN 7th Annual Kidney Cancer Research Summit on July 17-18, 2025. Dr. Randi Isaacs will discuss the company's WTX-124, a tumor-activated IL-2 INDUKINE molecule aimed at enhancing immune response in renal cell carcinoma. The presentation will highlight early clinical findings and the ongoing national trials for advanced or metastatic RCC.
Read more →HOWLWerewolf Therapeutics to Participate in the BIO International Convention
Werewolf Therapeutics will participate in the BIO International Convention from June 16-19, 2025, where Dr. Randi Isaacs will discuss conditionally activated biologics. This innovative approach aims to enhance anti-tumor activity while reducing toxicity. The company also launches the 'Full Moon Moment' initiative to promote its clinical trials, including the promising WTX-124 molecule.
Read more →HOWLWerewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference
Werewolf Therapeutics, Inc. will participate in the Jefferies Global Healthcare Conference from June 3-5, 2025. CEO Daniel J. Hicklin and CMO Randi Isaacs will engage in a fireside chat on June 5 at 4:20 PM EDT. The event will be accessible via a live webcast and archived for 90 days.
Read more →HOWLHonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics’ investigational novel conditionally activated IL-2 pro-drug WTX-124
A patient at HonorHealth Research Institute has achieved remission from advanced skin cancer for over a year after participating in a clinical trial for Werewolf Therapeutics' WTX-124, a novel conditionally activated IL-2 pro-drug. This promising outcome highlights the potential effectiveness of this investigational treatment in managing advanced skin cancer.
Read more →About Werewolf Therapeutics, Inc.
Headquarters200 TALCOTT AVENUE, WATERTOWN, MA, 02472
BIOPHARMAWATCH ELITE
Trade the next HOWL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime